Medtronic, Inc. MDT today announced that the U.S. Food and Drug Administration (FDA) approved its Revo MRI SureScan pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in